AR083835A1 - Factor h para el tratamiento de enfermedades autoinmunes del sistema nervioso - Google Patents

Factor h para el tratamiento de enfermedades autoinmunes del sistema nervioso

Info

Publication number
AR083835A1
AR083835A1 ARP110104208A ARP110104208A AR083835A1 AR 083835 A1 AR083835 A1 AR 083835A1 AR P110104208 A ARP110104208 A AR P110104208A AR P110104208 A ARP110104208 A AR P110104208A AR 083835 A1 AR083835 A1 AR 083835A1
Authority
AR
Argentina
Prior art keywords
factor
treatment
nervous system
autoimmune diseases
disease
Prior art date
Application number
ARP110104208A
Other languages
English (en)
Spanish (es)
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of AR083835A1 publication Critical patent/AR083835A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP110104208A 2010-11-10 2011-11-10 Factor h para el tratamiento de enfermedades autoinmunes del sistema nervioso AR083835A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1059311A FR2967071A1 (fr) 2010-11-10 2010-11-10 Facteur h pour le traitement de maladies auto-immunes du systeme nerveux

Publications (1)

Publication Number Publication Date
AR083835A1 true AR083835A1 (es) 2013-03-27

Family

ID=43608826

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104208A AR083835A1 (es) 2010-11-10 2011-11-10 Factor h para el tratamiento de enfermedades autoinmunes del sistema nervioso

Country Status (3)

Country Link
AR (1) AR083835A1 (fr)
FR (1) FR2967071A1 (fr)
WO (1) WO2012063007A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
EP0264166B1 (fr) 1986-04-09 1996-08-21 Genzyme Corporation Animaux transformés génétiquement sécrétant une protéine désirée dans le lait
US20020082227A1 (en) * 1999-09-30 2002-06-27 Scott Henry Use of oligonucleotides for inhibition of complement activation
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
EP2129686B1 (fr) 2007-03-20 2016-07-13 CSL Behring GmbH Procédés pour la production à l'échelle industrielle de préparations thérapeutiques du facteur h du complément pour le plasma humain

Also Published As

Publication number Publication date
WO2012063007A1 (fr) 2012-05-18
FR2967071A1 (fr) 2012-05-11

Similar Documents

Publication Publication Date Title
GT201200313A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
DOP2012000063A (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
CR20150358A (es) Derivados de exendina-4 fucionalizada
CR20150020A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
MX2016008448A (es) Conjugados de var2csa-farmaco.
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
CL2013001445A1 (es) Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer.
CR20110023A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
UY35037A (es) Composición antiparasitaria de amplio espectro de nitazoxanida,probióticos y prebióticos
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
AR083835A1 (es) Factor h para el tratamiento de enfermedades autoinmunes del sistema nervioso
EA201590782A1 (ru) Оксирановые амины
CL2015000310A1 (es) Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg.
CU20140058A7 (es) Nuevos 2h-indizoles como antagonistas del receptor ep-2
HN2010001125A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
UA84197U (ru) Способ медицинской реабилитации больных синдромом раздраженного кишечника, сочетанного с нейроциркуляторной дистонией

Legal Events

Date Code Title Description
FB Suspension of granting procedure